[68Ga]Ga-PSMA PET/CT:肝细胞癌显像的新方法
所有患者均未见放射性药物相关不良事件,肿瘤/肝比值(TLR)为3.6±2.1,SUVmax为13.5±7.1,5例(33%)患者治疗策略因此改变。
要点
- [68Ga]Ga-PSMA-11 PET/CT可在体内检测肝细胞癌PSMA表达,未见放射性药物相关不良事件。
- 肿瘤/肝比值(TLR)为3.6±2.1,SUVmax为13.5±7.1。
- 5例(33%)患者治疗策略因该PET/CT结果改变。
核心结论
- [68Ga]Ga-PSMA-11 PET/CT可在肝细胞癌患者体内检测PSMA表达,并有助于指导治疗策略。
研究设计与样本
- 全部患者接受增强MRI/CT、[68Ga]Ga-PSMA-11 PET/CT及病灶组织病理学验证。
主要发现
- 未见放射性药物相关不良事件。
- 视觉判读显示全部肝细胞癌患者[68Ga]Ga-PSMA-11摄取增高。
- 肿瘤/肝比值(TLR)为3.6±2.1,SUVmax为13.5±7.1。
- 新诊断与复发患者间SUV或TLR无显著差异。
- 血清肿瘤标志物(AFP、CA 19-9、CEA)浓度与PET参数间无统计学显著关系。
关键数值与推荐
- 5例(33%)患者的治疗策略因[68Ga]Ga-PSMA-11 PET/CT结果而改变。
- PSMA染色强度与分布可见异质性:假腺管型肝细胞癌仅少数血管弱反应,梁状型呈均匀强反应并伴热点。
临床怎么用
- 可考虑用[68Ga]Ga-PSMA-11 PET/CT在体内评估肝细胞癌PSMA表达并辅助制定治疗策略。
局限性
- 作者指出需进一步研究该方法在肝细胞癌中的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) is not only highly expressed on the surface prostate cancer cells but is also elevated during angiogenesis in other cancer cell types, including hepatocellular carcinoma (HCC). This study aimed to evaluate the feasibility of using PET/CT imaging with [68Ga]Ga-PSMA-11 in HCC and its impact on patient management. METHODS: Fifteen patients (13 men and two women; aged 55.6 ± 18.2 years) with HCC were enrolled in this prospective, single-institution study. All patients underwent contrast-enhanced MRI/CT, [68Ga]Ga-PSMA-11 PET/CT, and histopathological verification of lesions. RESULTS: No radiopharmaceutical-related adverse events were noted. Visual interpretation showed increased accumulation of [68Ga]Ga-PSMA-11 in all HCC patients. The tumor-to-liver ratio (TLR) was 3.6 ± 2.1, and the maximal standardized uptake value (SUVmax) was 13.5 ± 7.1. There were no significant differences in the SUVs or TLR between newly diagnosed and recurrent patients. No statistically significant relationship was found between serum concentration of tumor markers (i.e., AFP, CA 19-9, CEA) and PET parameters. Results of the [68Ga]Ga-PSMA-11 PET/CT changed the treatment strategy in five (33%) patients. PSMA staining showed visible heterogeneity in terms of intensity and distribution: the reaction was weak and only observed in a few vessels in pseudoglandular patterns of HCC, while it was homogeneously strong, with some hot spots, in trabecular patterns of HCC. CONCLUSION: [68Ga]Ga-PSMA-11 PET/CT can detect PSMA expression in vivo in patients with HCC and is useful for guiding treatment strategies. Further investigation of the clinical utility of this method in HCC is warranted.
引用
- Kunikowska J, Cieślak B, Gierej B, et al. [68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 32885272. doi:10.1007/s00259-020-05017-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。